Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Identifying risk factors for severe COVID-19 in patients with AML, MDS and ALL

In this video, Pinkal Desai, MD, MPH, Weill Cornell Medical College, New York, NY, shares some results from an analysis which aimed to identify risk factors for severe COVID-19 infection in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and acute lymphoblastic leukemia (ALL). First, Dr Desai explains the data hub that was used, the ASH RC COVID-19 Registry for Hematology, and the methods of obtaining data for the analysis. Dr Desai then explains why mortality rates were higher in these patients, drawing focus on the risk factors that were associated with severe COVID-19 infection, including having neutropenia and active primary disease at diagnosis. To conclude, Dr Desai discusses plans to look at the more recent data in the registry, allowing for a comparison to be made between 2020 and 2021. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.